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Abstract
Introduction The objective of this study was to determine
whether serum biomarkers for degradation and synthesis of the
extracellular matrix of cartilage are associated with, and can
predict, radiographic damage in patients with rheumatoid
arthritis (RA).
Methods Clinical and radiographic data of 87 RA patients were
recorded 1 year after disease onset and then annually up to four
years. Serum concentrations of four cartilage biomarkers were
determined at these time points: a neoepitope formed by
collagenase cleavage of type II collagen (C2C), a neoepitope
formed by collagenase cleavage of type II collagen as well as
type I collagen (C1,2C), a carboxy propeptide of type II
procollagen formed during synthesis (CPII), and a cartilage
proteoglycan aggrecan turnover epitope (CS846-epitope).
Biomarker concentrations between patients with rapid
radiographic progression (>7.3 Sharp/van der Heijde units per
year) and those with slow radiographic progression (<2.3 units
per year) were compared. In addition, we evaluated the long-
term and short-term predictive value of each biomarker for
progression of radiographic damage.
Results Patients with rapid radiographic progression had higher
C2C, higher C1,2C, and higher CS846-epitope levels than
slow progressors. CPII levels showed no differences. Most
importantly, the long-term radiographic progression for C2C, for
C1,2C, and for CS846-epitope can be predicted by the
biomarker value at year 1 after disease onset. C2C was also a
predictor for joint space narrowing and annual radiographic
damage during the subsequent year.
Conclusion This study shows that the concentration of serum
biomarkers of cartilage collagen breakdown and proteoglycan
turnover, but not of collagen synthesis, are related to joint
destruction in RA. The use of these biomarkers may be of value
when studying progression of joint damage in patients with RA.
Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory disease
characterized by joint destruction. Inflammation of the synovial
tissue causes damage to articular cartilage and subchondral
bone of the joints [1]. In established RA, radiographs reveal
joint space narrowing as a result of cartilage loss and charac-
teristic erosions of bone. Different radiographic scoring meth-
ods, such as those of Sharp/van der Heijde [2] or Larsen [3],
are used to determine damage in these joints.
The progression of joint damage as measured on radiographs
differs significantly between patients. In some cases the pro-
AUC = area under the curve; C1,2C = marker for degradation of type I collagen and type II collagen in cartilage; C2C = marker for degradation of 
type II collagen in cartilage; CPII = marker for synthesis of the procollagen of type II collagen cartilage; CS846-epitope = marker for aggrecan turnover 
in cartilage; ELISA = enzyme-linked immunosorbent assay; ESR = erythrocyte sedimentation rate; GEE = generalized estimated equation; IQ0.25–0.75 
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gression of joint damage is very slow, whereas in other cases
extensive destruction can occur within a few years after dis-
ease onset [4]. Radiographs only reveal gross anatomical
changes. It usually takes at least one year before significant
changes in joint damage can be observed. This delay means
there is a need for more sensitive measures that can detect the
process of bone and cartilage damage, which may therefore
be predictive of radiographically assessed progression of joint
damage.
As a result of cartilage damage, key components of the extra-
cellular matrix are lost. This usually results in increased matrix
turnover involving increased matrix synthesis in an attempt to
replace essential structural components. These turnover prod-
ucts enter body fluids as 'biomarkers', where they can now be
detected by sensitive immunoassays in accessible fluids such
as serum and urine [5-9]. These biomarker assays may be of
use in distinguishing RA patients with rapid progressive and
slow progressive joint damage, and may help to identify the
severity of joint disease resulting in radiographic damage.
It has been shown in previous studies that a neoepitope
marker for degradation of type II collagen in cartilage (C2C),
generated by collagenases, is increased in the serum and
urine of patients with RA [10]. A related neoepitope COL2-3/
4CShort (a marker for degradation of type I collagen and type II
collagen in cartilage [C1,2C]) can be detected in type II colla-
gen as well as in type I collagen [11]. Elevated levels of urine
CTX-II (a c-telopeptide degradation product of type II colla-
gen) have been demonstrated to be associated with increased
radiographic damage in RA [12]. Levels of an epitope present
in chondroitin sulfate of the cartilage proteoglycan aggrecan
(a marker for aggrecan turnover in cartilage [CS846-epitope])
are elevated in serum in chronic RA, although the levels are
depressed in rapid progressive RA [13]. The CS846-epitope
is found only on the largest aggrecan molecules [14].
Increased serum levels may therefore reflect increased turno-
ver of newly formed matrix, which is normally not seen in adult
cartilage. Levels of a marker for synthesis of the procollagen of
type II collagen cartilage (CPII), the C-propeptide of type II car-
tilage collagen, are elevated in RA patients [13,15]. CPII is a
marker of increased collagen type II synthesis, and higher val-
ues indicate an attempt to repair.
Although the relationship between these markers and joint
damage in RA is important to establish, it is more important to
determine whether these markers have the capacity to predict
the development of joint damage, and hence disease progres-
sion. Validation of existing and new biomarkers in this respect
is therefore very important in more than just one study before
these markers can be used as an additional prognostic meas-
urement in daily practice. More recently, ELISA assays for
C1,2C, for C2C, for CS846-epitope, and for CPII have
become commercially available. The goal of the present study
was therefore to determine whether there is a relationship
between concentrations of these serum biomarker and joint
damage as well as the progression of joint damage.
Evaluations of this kind should preferably be performed in a
cohort of patients with early RA, for whom both radiographic
and clinical data have been assessed in detail during the
course of disease. We have studied a cohort of RA patients
followed from the onset of disease (the Utrecht Rheumatoid
Arthritis Cohort [16,17]) for which annual clinical and radio-
graphic data were available. For this study we determined
serum biomarker levels annually 1 year from onset and for the
subsequent three years.
Patients and methods
Patients
From 1990 to 1998, patients with recent onset of RA accord-
ing to the 1987 American College of Rheumatology revised
criteria [18] and disease duration <1 year were recruited from
six rheumatology departments in the region of Utrecht, The
Netherlands, to participate in a randomized, prospective clini-
cal trial. At entry to the trial, patients were randomly assigned
to a group for early initiation with disease-modifying antirheu-
matic drug therapy (to either start with methotrexate, intramus-
cular gold, or hydroxychloroquine) or to a group for delayed
initiation of disease-modifying antirheumatic drugs.
All patients except two used disease-modifying antirheumatic
drugs for some period of time during the follow-up. The proto-
col of this trial stated that the use of glucocorticoids should be
avoided as much as possible during the study period. Only six
patients had to use glucocorticoids within the first year after
diagnosis. The treatment strategy was decided after 2 years
by the treating rheumatologist. There were no statistically sig-
nificant differences in any of the four biomarker levels between
the four treatment groups at 1 year. This study was approved
by the medical ethical committees of all participating hospitals,
and all patients gave written informed consent before entering
the study. The study design and the results of this 2-year treat-
ment trial have been described extensively in previous reports
[17,19].
Study design
To avoid unknown effects directly associated with the initial
response to treatment, the evaluation of biomarkers com-
menced 1 year after the initiation of treatment and continued
for a period of 3 years thereafter. Clinical variables were there-
fore assessed, radiographs taken, and blood samples col-
lected and stored at 1, 2, 3 and 4 years after diagnosis. For
this study we used all samples that were still available from the
cohort described and those samples that had never been
thawed before.
Clinical variables
The following clinical variables were assessed: erythrocyte
sedimentation rate (ESR, mm/h1st), morning stiffness (rangeAvailable online http://arthritis-research.com/content/8/1/R31
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0–720 minutes), visual analogue scale for pain (range, 0–100
mm; 100 mm = worst score), visual analogue scale for general
well-being (range 0–100 mm; 100 mm = worst score), func-
tional disability (Health Assessment Questionnaire, Dutch ver-
sion) (range, 0–3; 3 = worse functional ability), rheumatoid
factor (positive/negative), either by means of the Waaler Rose
test (positive >20 U/ml) or by means of the Latex fixation test,
and joint score (Thompson joint score, a weighted score
including both 38 tender joints and 38 swollen joints, range 0–
534 [20]). The Thompson joint score is found to be well cor-
related with other frequently used joint scores [21].
Radiographic damage
Radiographs of the hands and feet (posterior–anterior view)
were taken once every year and were scored in chronological
order according to the modified Sharp/van der Heijde method
[22] by two observers who were blinded for clinical features.
Differences in total scores per patient of more than 25% were
discussed until agreement was reached. The intraclass corre-
lation coefficient between two sets of scores was 0.98, indi-
cating excellent agreement [4]. The total radiographic damage
score is the sum of the joint space narrowing and the erosion
scores of both hands and feet, ranging between 0 and 448 (a
higher score indicating more damage).
Biomarker analyses
Four biomarkers were evaluated — namely C1,2C, C2C,
CS846-epitope, and CPII. All assays are described and were
used as recommended by the manufacturer (Ibex, Montreal,
Canada).
The C1,2C competitive inhibition ELISA assay (a cartilage/
skin/bone collagen breakdown assay) measures the carboxy
terminus of the primary cleavage site (Col 2–3/4CShort
epitope) generated in type I and type II collagens by colla-
genases [11].
The C2C competitive inhibition ELISA (a cartilage breakdown-
specific assay) measures a related carboxyterminal
neoepitope created by the cleavage of only type II collagen by
collagenases. This longer neoepitope is specific for type II col-
lagen [10].
The CS846 ELISA assay measures an epitope on chondroitin
sulfate chains of the largest cartilage proteoglycan aggrecan
[14]. Differences in the serum epitope content have previously
been observed in patients with different rates of RA progres-
sion [13]. An ELISA format was used in the present study,
whereas a radioimmunoassay format was used in previous
studies [13,14].
Another ELISA assay was used to measure the synthesis of
type II procollagen by detection of the carboxy propeptide
(CPII), which is cleaved from type II procollagen following
release of newly synthesized procollagen into the matrix [15].
A radioimmunoassay format was employed in previous studies
[13,15].
The intraday (n = 20) and interday (n = 200) coefficients of
variance for each biomarker were, respectively: for C2C, 10–
17% and 14%; for C1,2C, 5–14% and 13%; for CS846-
epitope, 4–12% and 12%; and for CPII, 11–18% and 16%.
The interassay coefficients of variance for all the assays deter-
mined for 30 masked pairs were in the range of 6.4–11.5%
(KD Brandt, SA Mazzuca, T Lobanok, AR Poole, unpublished
data).
Because combinations of markers measuring the balance
between different processes such as the synthesis and degra-
dation or differential degradation of cartilage collagen might
provide additional information, the following three ratios of
biomarkers, and the reverse of these ratios, were calculated:
C1,2C/C2C ratio, C2C/CPII ratio, and (C1,2C/C2C)/CPII
ratio.
Statistical analysis
Statistical analyses were performed using the SPSS statistical
package ver. 11.5 (2000) (SPSS Institute, Chicago) and SAS
statistical package ver. 4.16 (1994) (SAS Institute, Cary, NC).
Clinical variables
Spearman rank correlations were calculated to determine pos-
sible correlations between biomarker levels and (several) out-
comes of disease activity at year 1. Furthermore, we compared
biomarker values at year 1 for women versus men, and for
patients with a positive rheumatoid factor test versus patients
with a negative rheumatoid factor test at 1 year (Mann–Whit-
ney U test). We also calculated the correlation between the
mean within-patient biomarker concentration over time and the
average disease activity over time, calculated as the area
under the curve standardized to time (AUC).
Associations with radiological damage
Two groups of patients were distinguished to assess whether
biomarker levels could discriminate between those patients
with slow versus rapid radiographic progression. The annual
progression rate (units/year) was defined as the difference
between the radiographic damage score measured at 4 years
and the score measured at 1 year, divided by three. If no radi-
ographs were obtained at one of these two points, the pro-
gression rate was calculated based on available scores. First,
the median biomarker levels of patients with slow radiographic
progression (lowest tertile of annual progression rate) were
compared with biomarker levels of patients with rapid radio-
graphic progression (highest tertile of mean annual progres-
sion rate), separately at each assessment point in time. Levels
of biomarker concentrations are shown as the median (IQ0.25–
0.75), and the statistical significance of the differences was
tested by a nonparametric Mann–Whitney U test (P < 0.05).Arthritis Research & Therapy    Vol 8 No 1    Verstappen et al.
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Biomarker ability to predict progression of radiographic 
damage
Most importantly, with respect to clinical relevance of biomar-
ker evaluation, we determined whether the biomarker value
assessed 1 year after disease onset could predict radiological
progression during the subsequent years, where the individual
patients' rate of progression was estimated as the slope of
radiological scores over time (years). Multivariable generalized
estimated equation (GEE) analyses, an extension of multiple
linear regression for longitudinal repeated-measurements data
[23], were performed separately for log-transformed values of
total radiographic damage score, erosion score, and narrow-
ing score.
Each GEE model estimated three regression coefficients
related to the association between a given biomarker and pro-
gression of the damage score representing the effects of,
respectively, the biomarker value at year 1, the time since year
1, and the biomarker-by-time interaction. Notice that the first
coefficient represents a variable fixed in time, whereas the lat-
ter two coefficients are assigned to time-dependent variables
whose values change over time. The hypothesis that the pro-
Table 1
Patient characteristics, disease-modifying antirheumatic drug (DMARD) use, and biomarker concentrations 1 year after diagnosis
Age (years) 58 ± 13
Gender, women (%) 63
Rheumatoid factor, positive (%) 68
Erythrocyte sedimentation rate (mm/h1st) 25 ± 25
Joint score, Thompson 52 ± 77
Morning stiffness (min) 44 ± 88
Visual analogue scale pain (mm) 24 ± 25
Visual analogue scale general well-being (mm) 31 ± 26
Functional disability score, Health Assessment Questionnaire 0.96 ± 0.70
Radiographic damage, erosions 7.2 ± 8.3
Radiographic damage, narrowing 3.7 ± 4.1
Total radiographic damage score, Sharp/van der Heijde 10.9 ± 11.2
DMARD use [number (%)]
No DMARD 6 (7)
Intramuscular gold 19 (22)
Methotrexate 26 (30)
Hydroxychloroquine 21 (24)
D-penicillamine 7 (8)
Sulfasalazine 4 (5)
Imuran 1 (1)
Auranofin 3 (3)
Biomarker concentrations
C2C (ng/ml) 130 ± 62
C1,2C (ng/ml) 514 ± 287
CS846-epitope (ng/ml) 61 ± 22
CPII (ng/ml) 242 ± 180
Values presented as the mean ± standard deviation for continuous variables and percentages for categorical variables. Rheumatoid factor 
positive, patients testing positive either at diagnosis or 1 year. C2C, a marker for degradation of type II collagen in cartilage; C1,2C, a marker for 
degradation of type I and type II collagen in cartilage; CS846-epitope, a marker for aggrecan turnover in cartilage; CPII, a marker for synthesis of 
the pro-collagen of type II collagen cartilage.Available online http://arthritis-research.com/content/8/1/R31
Page 5 of 9
(page number not for citation purposes)
gression rate is associated with the one year biomarker value
was tested by assessing the statistical significance of the
interaction coefficient. Its value of the interaction coefficient
measured the strength of this relation. This analysis was
repeated after adjusting for patients' gender and age one year
after inclusion.
Along with the long-term predictive value, we also evaluated
the short-term predictive value of each biomarker for radiolog-
ical progression during the subsequent year. GEE generaliza-
tion of the multivariable linear regression was again used. The
dependent variable was defined as the difference between the
log-transformed radiological scores at year (i + 1) versus the
scores year (i) using the differences of year 2 minus year 1, of
year 3 minus year 2, and of year 4 minus year 3; each subject
therefore contributed to up to three differences. The inde-
pendent variables included the biomarker score at year i as
well as age and gender.
Results
Patients
The study included 87 patients with RA. Serum samples were
available for 85 patients at one year, for 79 patients at two
years, for 72 patients at three years, and for 77 patients at four
years. Demographic and clinical characteristics of these
patients 1 year after diagnosis are summarized in Table 1. The
mean age was 58 years, and 63% of the participants were
female.
Clinical and demographic variables and biomarkers
One year after diagnosis we did not find statistically significant
differences in median (IQ0.25–0.75) biomarker values between
women and men, while age was not correlated with any of the
four biomarkers. No significant differences were also found in
biomarker levels between the four assigned treatment groups.
All median biomarker concentrations, except for CPII (174 ver-
sus 173, P = 0.414), were statistically significantly higher for
patients with a rheumatoid factor positive test at 1 year (n =
62) compared with patients with a negative test (n = 24): 136
versus 111 for C2C (P = 0.012); 535 versus 371 for C1,2C
(P  = 0.009), and 64 versus 47 for CS846-epitope (P  =
0.022). Of all other disease-related variables at year 1, the
ESR was positively correlated with C2C (r  = 0.230, P  =
0.035) and with C1,2C (r = 0.256, P = 0.019), and almost
statistically significantly correlated with CS846-epitope (r =
0.215, P = 0.051), but not with CPII (r = 0.122, P = 0.273).
The results of these correlations at 1 year remained similar
when taking into account the AUC for clinical variables and the
mean biomarker concentrations over time. The AUC ESR cor-
related with C2C (r = 0.226, P = 0.035), with C1,2C (r =
0.261, P = 0.015), and with CS846-epitope (r = 0.238, P =
0.028), but not with CPII (r = 0.127, P = 0.245). In addition,
of all other clinical variables measured, the Thompson joint
score at year 1 was only correlated with C2C, although no
such correlation was observed for the AUC Thompson score.
It was shown in previous studies that the body mass index cor-
related with biomarker values [24,25]. To determine whether
the body mass index could possibly be a confounding factor,
we included the body mass index in our analyses of 74
patients for whom both height and weight were measured at
diagnosis. No association for body mass index and biomarker
concentrations was found (all P values above 0.05); we there-
fore did not control for body mass index in further analyses.
Associations between biomarker levels and 
radiographic damage
Patients with rapid radiographic progression (highest tertile,
>7.35 units per year) had higher median C2C levels, C1,2C
levels, and CS846-epitope levels at almost all time points,
except for C2C at year 4 and for C1,2C at year 1, than patients
with slow radiographic progression (lowest tertile, <2.33 units
per year) (Figure 1). In contrast, the median values of CPII
were unaffected by radiographic progression at all annual
assessment points (Figure 1).
Differences were found for the median radiographic progres-
sion rates at 1 year when the highest tertile of each biomarker
value was compared with the remainder of the population at
year 1. Statistically significant differences were found for C2C
(7.8 versus 3.5, P = 0.030) and for CS846-epitope (7.5 ver-
sus 2.7, P = 0.06). However, the median progression rate was
not statistically significant for C1,2C (5.5 versus 3.8, P  =
0.128) and for CPII (6.6 versus 3.7, P = 0.127) at year 1.
Assessing ability of biomarkers to predict progression of 
radiographic damage
Table 2 presents the results of the GEE analyses of the
repeated measurements of the radiological scores (specifi-
cally, for each combination of one of the four biomarkers and
one of the three damage scores). A statistically significant
interaction was found for C2C, for C1,2C, and for CS846-
epitope. This means that the progression rate is affected by
the value of the biomarker 1 year after disease onset. In such
a case, the two progression rate columns of Table 2 show how
much the estimated annual rates of change in the damage
score increase due to a change of one standard deviation in
the biomarker value. For example, there is a statistical signifi-
cant interaction between time and C2C (P  = 0.03). For
patients with the mean C2C value, the total radiographic dam-
age score increases by 29% per year; whereas for patients
with C2C one standard deviation above the mean, the average
annual increase is as high as 35%. The relative percentage
increase of the progression rate of the radiographic damage
score per one standard deviation increase in C2C is therefore
21%.
If the interaction is nonsignificant (P > 0.05) there is no evi-
dence that the progression rate varies with the baseline
biomarker value. The association between a higher C2C/CPII
ratio and faster progression was marginally significant (P =Arthritis Research & Therapy    Vol 8 No 1    Verstappen et al.
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0.055). No other associations were found with the predefined
ratios of biomarkers and radiographic progression scores.
After a subdivision of the total radiographic damage score into
narrowing and the erosion score, higher C2C remained statis-
tically significantly associated with a faster progression of the
narrowing score (P = 0.019) and only an elevated CS846-
epitope was associated with a faster progression of the ero-
sion score (P = 0.014). Adjustment by age and sex did not
change these results (data not shown).
In addition to the long-term predictive value of the biomarker
levels measured at year 1, we also focused on the putative
association between a biomarker value observed at a given
visit and the progression during the subsequent year. Higher
C2C values were associated with a statistically significantly
increased progression of radiographic damage during the next
year. An increase in the current C2C value by one standard
deviation (for example, by 62 units) was associated with a 5%
relative increase in the value in the following year of the radio-
graphic damage score among subjects who have the same
current score. Moreover, higher current values of both C1,2C
and CS846-epitope and lower more recent values of the CPII/
C2C ratio were all marginally associated with an increased
progression of radiological damage in the subsequent year.
Associations of recent biomarkers with progression of erosion
or the narrowing score was only apparent for C2C, which was
statistically significantly associated with the progression of the
joint space narrowing score over the following year (for exam-
ple, a relative increase of 6.4% in the joint space narrowing
score during the next year caused by a one standard deviation
increase in the C2C value.
Discussion
The search for markers to predict radiographic joint damage is
important because differences in clinical parameters such as
inflammation might not always correlate with radiographic out-
Figure 1
Boxplots of biomarkers levels during follow-up (1–4 years) for patients with slow radiographic progression (<2.33 Sharp/van der Heijde units per  year; shaded boxplot) versus patients with rapid radiographic progression (>7.35 Sharp/van der Heijde units per year; white boxplot) based on the  33rd and 66th percentile of annual radiographic progression Boxplots of biomarkers levels during follow-up (1–4 years) for patients with slow radiographic progression (<2.33 Sharp/van der Heijde units per 
year; shaded boxplot) versus patients with rapid radiographic progression (>7.35 Sharp/van der Heijde units per year; white boxplot) based on the 
33rd and 66th percentile of annual radiographic progression. Boxplots show the median value and (IQ0.25–0.75). Lines outside boxes represent the 
10th and 90th percentiles. **Statistically significant (P < 0.05) difference between the group of patients with rapid radiographic progression versus 
the group of patients with slow radiographic progression. C2C, marker for degradation of type II collagen in cartilage; C1,2C, marker for degradation 
of type I collagen and type II collagen in cartilage; CPII, marker for synthesis of the procollagen of type II collagen cartilage; CS846-epitope, marker 
for aggrecan turnover in cartilage.Available online http://arthritis-research.com/content/8/1/R31
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come reflective of skeletal damage. Prognostic indicators of
joint damage are sought that identify the processes that result
in joint damage and which may predict the progression of joint
damage. Radiographs only record the outcome, namely joint
damage. Hence measurement of a product of the process
resulting in joint damage may be of value in predicting such an
outcome. A number of assays have recently become available
to measure the degradation and repair of bone and cartilage.
These biomarkers have been tested mainly in patients with
osteoarthritis [8,9], and to a lesser extent in patients with RA
[7,12]. Only urinary CTXI [26] and CTXII [12], markers of the
degradation of type I collagen and type II collagen, respec-
tively, have presently been demonstrated to be predictive of
joint damage in RA.
In the present study, a set of other cartilage biomarkers of joint
damage and turnover was evaluated. We measured not only
the degradation (C1,2C and C2C), but also the turnover and
synthesis (CS846-epitope and CPII, respectively) of cartilage.
Interestingly, it was the biomarkers for degradation of collagen
(C2C and C1,2C) and turnover of aggrecan (CS846-epitope),
rather than for the synthesis of cartilage collagen (CPII), that
were significantly elevated in patients with rapid radiographic
progression when compared with patients with slow progres-
sion. It thus seems that the development of radiographic dam-
age during the first years after diagnosis is more a reflection of
increased degradation of collagen and enhanced turnover of
proteoglycans rather than a lack of synthesis of cartilage col-
lagen. This lack of association between CPII and radiographic
damage corroborates previous findings in a cohort of RA
patients [13].
More importantly, C2C, C1,2C and CS846-epitope measured
at one year were each predictors of radiographic damage dur-
ing the subsequent years. Furthermore, C2C levels measured
at a given year predicted radiographic progression during the
subsequent year. These results are in perfect agreement with
the studies showing urinary CTXII, a type II collagen degrada-
tion marker for cartilage loss, to be associated with concurrent
severity of radiographic damage and to predict its future pro-
Table 2
Association between biomarker values measured at year 1 and subsequent radiographic progression rates
Biomarker P value for interactiona Estimated annual progression rate
Mean biomarker (%)b Mean + one standard deviation (%)c
C2C
Damage 0.030* 29 35
Erosion 0.156 24 27
Narrowing 0.019* 31 40
C1,2C
Damage 0.033* 26 30
Erosion 0.195 25 29
Narrowing 0.271 32 36
CPII
Damage 0.777 28 28
Erosion 0.816 25 25
Narrowing 0.136 33 41
CS846-epitope
Damage 0.039* 28 34
Erosion 0.014* 27 36
Narrowing 0.476 32 35
For each biomarker, the results of the multivariable generalized estimated equation regression model for longitudinal analyses between biomarker 
value at year 1 after inclusion and subsequent (repeated over time) values of the log-transformed progression score are presented. C2C, marker 
for degradation of type II collagen in cartilage; C1,2C, marker for degradation of type I collagen and type II collagen in cartilage; CPII, marker for 
synthesis of the procollagen of type II collagen cartilage; CS846-epitope, marker for aggrecan turnover in cartilage. aP < 0.05 indicates that the 
change in the rate of progression depends significantly on the biomarker value at year 1; *interaction statistically significant (P < 0.05). 
bPercentage increase of radiographic damage score per year for patients with a mean value of biomarker 1 year after disease onset. cPercentage 
increase in radiographic damage scores per year for patients with a value one standard deviation above the mean biomarker value 1 year after 
disease onset.Arthritis Research & Therapy    Vol 8 No 1    Verstappen et al.
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gression in RA [12]. In our analyses, as might be anticipated,
it was specifically joint space narrowing (for example, cartilage
loss), and with that type II collagen loss, that could be pre-
dicted by serum C2C levels – not only each year, but also over
the period of study. This no doubt reflects the fact that C2C is
a specific marker for cleavage of type II collagen, which is pri-
marily present in hyaline cartilage and the intervertebral discs
with relatively very small amounts present elsewhere in other
tissues, such as in entheses and in the vitreous of the eye. This
was not true for aggrecan turnover (CS846-epitope), how-
ever, which was only associated with total radiographic dam-
age score and with the erosion score, and not with narrowing
score as one would expect.
Another interesting finding of this study is that biomarker con-
centrations differed extensively between patients but mean
concentrations remained remarkably stable over time for all
four biomarkers, suggesting that the process of cartilage deg-
radation follows a continuous stable course after 1 year of
diagnosis of RA. Interestingly, we have also found a linear pro-
gression of radiographic damage in our cohort during the first
years after diagnosis [4].
In this study, we further determined whether biomarker levels
correlated with clinical parameters or were associated with
demographic characteristics. Only the ESR, both at one year
and over time, was correlated with C2C, with C1,2C, and with
CS846-epitope concentrations. Also, patients who had a pos-
itive rheumatoid factor test at 1 year had significantly higher
levels of C2C, of C1,2C, and of CS846-epitope. Our primary
goal was to study the pathogenic role of biomarkers alone in
relation to radiographic progression, and we therefore did not
correct for the ESR and rheumatoid factor. When biomarkers
levels at 1 year were adjusted for the ESR and rheumatoid fac-
tor obtained at 1 year, the predictive ability for total radio-
graphic progression over 4 years decreased, but was still
evident for C2C (P = 0.065), for C1,2C (P = 0.026), and for
CS846-epitope (P = 0.017).
We used a random set of samples because we wanted a rep-
resentative RA population. We therefore think that the results
could improve if we had sorted samples based on extreme
high values of radiographic damage score versus patients with
hardly any damage. In this study we did not want to determine
the influence of treatment on change of biomarker levels, but
rather the association between biomarker levels over the years
with radiographic damage during follow-up and the predictive
ability of biomarker levels for radiographic damage. We there-
fore started sera samples analyses one year after the start of
treatment since changes in disease activity are considerable in
the first year after initiating treatment, varying significantly
between patients. For CTX-II and CTX-I it was found that the
CTX-I values decreased during the first six months because of
treatment, but after 1 year both CTX-I and CTX-II values were
similar to baseline values [27]. More longitudinal studies are
necessary to better determine the clinical value of the biomar-
kers used in our investigation. In these studies the predictive
ability of biomarkers associated with cartilage breakdown
measured at diagnosis, and before treatment, should also be
evaluated. In general, the identification of biomarkers that can
be used as a prognostic tools in daily practice to predict the
onset and progression of joint damage remains the goal of
these studies in RA, and especially in osteoarthritis [28],
where the ability to predict progression of cartilage destruc-
tion and outcome is perhaps of even greater importance.
Conclusion
This study shows that biomarkers of cartilage collagen break-
down (C2C and C1,2C) and proteoglycan turnover (CS846-
epitope), but not biomarkers of synthesis (CPII), are related to
specific joint space narrowing and erosions in RA. Specifically,
C2C (the marker for collagen type II damage) could predict
subsequent short-term as well as long-term radiographic dam-
age in RA, and more specifically joint space width narrowing.
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